PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: Mark Stirrat Orrick, Herrington & Sutcliffe, LLP 4 Park Plzaz, Suite 1600 Irvine, CA 92614-2558	PCT NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION (PCT Rule 44.1)			
	Date of mailing (day/month/year) 23 NOV 2007			
Applicant's or agent's file reference CRMD-016WO	FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No. PCT/US 06/34130	International filing date (day/month/year) 29 August 2006 (29.08.2006)			
Applicant Cardiomind, Inc.				
1. The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith. Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46): When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report. Where? Directly to the International Bureau of WIPO, 34 chemin des Colombettes 1211 Geneva 20, Switzerland, Facsimile No.: +41 22 740 14 35 For more detailed instructions, see the notes on the accompanying sheet. 2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith. 3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that: the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.				
4. Reminders Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication. The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date. Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices. In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months. See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.				
Name and mailing address of the ISA/US	Authorized officer:			

Form PCT/ISA/220 (January 2004)

Facsimile No. 571-273-3201

Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450

Lee W. Young

PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference CRMD-016WO	FOR FURTHER ACTION	see Form PCT/ISA/220 as well as, where applicable, item 5 below.
International application No. PCT/US 06/34130	International filing date (day/mo	onth/year) (Earliest) Priority Date (day/month/year) 02 November 2005 (02.11.2005)
Applicant Cardiomind, Inc.		
This international search report consis It is also accompanied by 1. Basis of the report a. With regard to the language, the international approximate a translation of the a translation furnis b. This international search authorized by or notified c. With regard to any nucle	as of a total of sheets. a copy of each prior art document the international search was carried uplication in the language in which international application into hed for the purposes of international report has been established taking to this Authority under Rule 91 (R	out on the basis of: it was filed. which is the language al search (Rules 12.3(a) and 23.1(b)). ag into account the rectification of an obvious mistage 43.6bis(a)). e disclosed in the international application, see Box No.
3. Unity of invention is lac	king (see Box No. III).	
	ibmitted by the applicant. hed by this Authority to read as fol	llows:
the text has been establis	abmitted by the applicant. Thed, according to Rule 38.2(b), by rom the date of mailing of this inter	this Authority as it appears in Box No. IV. The appli rnational search report, submit comments to this Autho
as suggested by th as selected by this as selected by this	be published with the abstract is Fig e applicant. Authority, because the applicant fa Authority, because this figure bette be published with the abstract.	ailed to suggest a figure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 06/34130

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows: This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. Group I: claims 1-2 are directed to a power supply for an implant delivery system.
Group II: claims 3-38 are directed to a stent delivery system.
The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because under PCT Rule 13.2 they lack the same or corresponding technical features for the following reasons:
Groups II does not include the inventive concept of a power supply.
Groups I does not include the inventive concept of a stent delievery system.
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US 06/34130

			1 01/00 00/	34130	
A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61F 2/06 (2007.10) USPC - 623/1.11 According to International Patent Classification (IPC) or to both national classification and IPC					
	DS SEARCHED		· · · · · · · · · · · · · · · · · · ·		
Minimum documentation searched (classification system followed by classification symbols) IPC(8) - A61F 2/06 (2007.10) USPC - 623/1.11					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched 424/423; 514/291, 604/500					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PubWEST(USPT,PGPB,EPAB,JPAB); Google Scholar; Google Search Terms Used: stent, sleeve, spring, eroding, erode, dissolve, dissolving, self expanding, alternating current, vessel, two phase					
C. DOCU	MENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where ap	opropriate, of the releva	ant passages	Relevant to claim No.	
Х	US 5,643,254 A (SCHELDRUP) 01 July 1997 (01.07.1 28-65.	997) Entire document, (especially col 5, In	1 and 2	
X Y	US 2005/0220836 A1 (FALOTICO et al.) 06 October 2 and para[0437].	3-7 9 and 16-21			
X - Y	US 6,168,618 B1 (FRANTZEN) 02 January 2001 (02.0 3, In 5-50 and col 7, In 2-20.	8, 10, 12, 14, 15, 30 and 35-38 9, 11, 13, 16-29 and 31-34			
Y	US 6,425,914 B1 (WALLACE et al.) 30 July 2002 (30.07.2002) FIG. 7 and col 7, ln 8-10.			11 and 34	
Y	US 4,553,545 A (MAASS et al.) 19 November 1995 (19.11.1995) FIG. 8, FIG. 9 and col 12, 2-44.			13, 24-29 and 31-33	
Y	US 2004/0260383 A1 (STELTER et al.) 23 December 2003 (23.12.2004) para[0033].			22-25	
Further documents are listed in the continuation of Box C.					
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "T" later document published after the international filing date or prior date and not in conflict with the application but cited to underst the principle or theory underlying the invention					
filing d		considered novel or cannot be considered to involve an			
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means 		"Y" document of particular relevance; the claimed invention ca considered to involve an inventive step when the docu combined with one or more other such documents, such comb			
(D) de constant de la			&" document member of the same patent family		
Date of the	actual completion of the international search	Date of mailing of the	e in Der Dati kalan slehr	ാറക 7rt	
10 October 2007 (10.10.2007)		23 NOV 2007			
Name and mailing address of the ISA/US Authorized officer:					
	T, Attn: ISA/US, Commissioner for Patents O, Alexandria, Virginia 22313-1450	BCT Holodock: 571 272 4200	Lee W. Young		

PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

Facsimile No. 571-273-3201

PATENT COOPERATION TREATY

To: Mark Stirrat Orrick, Herrington & Sutcliffe, LLP 4 Park Plaza, Suite 1600 Irvine, CA 92614-2558		PCT WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY	
			(PCT Rule 43bis.1)
		Date of mailing (day/month/year)	23 NOV 2007
Applicant's or agent's file reference		FOR FURTHER AC	
CRMD-016WO		See paragraph 2 below	
International application No.	International filing date	1000	Priority date (day/month/year)
PCT/US 06/34130	29 August 2006 (29	9.08.2006)	02 November 2005 (02.11.2005)
International Patent Classification (IPC) IPC(8) - A61F 2/06 (2007.10)	or both national classifica	tion and IPC	
Applicant Cardiomind, Inc.			
This opinion contains indications re	lating to the following ite	ms:	
<u>~</u>			
	.p		
Box No. II Priority			ecten and industrial applicability
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			sop and industrial approachies
Box No. IV Lack of unity			
Box No. V Reasoned statement under Rule 43bis. 1(a)(i) with regard to novelty, inventive step or industrial a citations and explanations supporting such statement Box No. VI Certain documents cited			elty, inventive step or industrial applicability;
Box No. VII Certain defec	ets in the international app	lication	
Box No. VIII Certain obse			
International Preliminary Examinit other than this one to be the IPEA opinions of this International Searce	and the chosen IPEA has being Authority will not be e, considered to be a writt ropriate, with amendment ion of 22 months from the /ISA/220.	notified the Internation e so considered. en opinion of the IPEA,	be considered to be a written opinion of the oply where the applicant chooses an Authority all Bureau under Rule 66.1 bis(b) that written the applicant is invited to submit to the IPEA of 3 months from the date of mailing of Former expires later.
Name and mailing address of the ISA/U	JS Date of completion o	f this opinion	Authorized officer:
Mail Stop PCT, Attn: ISA/US	10 October 2007		Lee W. Young
Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-14	50 TO October 2007	(10.10.2001)	PCT Helpdesk: 571-272-4300

PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

Facsimile No. 571-273-3201

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US 06/34130

Box	No.	I Basis of this opinion
1	Witl	h regard to the language, this opinion has been established on the basis of:
••	\boxtimes	the international application in the language in which it was filed.
	百	a translation of the international application into which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2.		This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a))
3.	Wit esta	h regard to any nucleotide and/or amino acid sequence disclosed in the international application, this opinion has been ablished on the basis of:
	a.	type of material
		a sequence listing
		table(s) related to the sequence listing
	b	format of material
	J.	on paper
		in electronic form
	c.	time of filing/furnishing
		contained in the international application as filed
		filed together with the international application in electronic form furnished subsequently to this Authority for the purposes of search
		Infinished subsequently to ans radioticy for the purposes of the second
4.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5.	Ad	Iditional comments:

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US 06/34130

Box No. IV Lack of unity of invention	
1. In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has, within the applicable time limit:	
paid additional fees	
paid additional fees under protest and, where applicable, the protest fee	
paid additional fees under protest but the applicable protest fee was not paid	
not paid additional fees	
2. This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applicant to pay additional fees.	
3. This Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 13.3 is	
complied with	
not complied with for the following reasons: This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.	
Group I: claims 1-2 are directed to a power supply for an implant delivery system.	
Group II: claims 3-38 are directed to a stent delivery system.	
The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because under PCT Rule 13.2 they lack the same or corresponding technical features for the following reasons:	
Groups II does not include the inventive concept of a power supply.	
Groups I does not include the inventive concept of a stent delievery system.	
None of these technical features are common to the other groups, nor do they correspond to a special technical feature in the other groups. Therefore, unity of invention is lacking.	
	١
	ļ
-	
4. Consequently, this opinion has been established in respect of the following parts of the international application:	
all parts	
the parts relating to claims Nos.	-

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US 06/34130

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims Claims	6, 9, 11, 13, 16-29 and 31-34 1-5, 7, 8, 10, 12, 14, 15, 30 and 35-38	YES NO
Inventive step (IS)	Claims Claims	None 1-38	YES NO
Industrial applicability (IA)	Claims Claims	1-38 None	YES NO

2. Citations and explanations:

Claims 1 and 2 lack novelty under PCT Article 33(2) as being anticipated by US 5,643,254 A to Scheldrup et al. (hereinafter 'Scheldrup').

As per claim 1, Scheldrup describes a power supply for an implant delivery system employing at least one electrolytically erodable element (electrolytic detachment of an embolic device, (Abstract)), the improvement comprising: adaptation of the power supply to provide an AC voltage profile with a peak-to-peak configuration of at least about 5V (the amplifier delivers constant DC current with AC superposition, (col 7, ln 14-16); A positive electric current ... at 0.1-6 volts, (col 5, ln 28-30)) and a DC voltage signal of at least about 1V (A DC current of between ... 0.1 to 6 volts, (col 5, ln 63-65)).

As per claim 2, Scheldrup describes method of implant delivery, the method comprising: introducing an implant delivery system in an electrolytic fluid (Electrolytic separation of a device from a guidewire may be facilitated by means of the assembly 100 shown in FIG. 2, (col 3, In 55-58)); and applying electrical power to an electrolytically erodable member, the power AC voltage profile with a peak-to-peak configuration of at least about 5V (the amplifier delivers constant DC current with AC superposition, (col 7, In 14-16); A positive electric current ... at 0.1-6 volts, (col 5, In 28-30)), and a DC voltage signal of at least about 1V (A DC current of between ... 0.1 to 6 volts, (col 5, In 63-65)).

Claims 3-5 and 7 lack novelty under PCT Article 33(2) as being anticipated by US 2005/0220836 A1 to Falotico et al. (hereinafter 'Falotico').

As per claim 3, Falotico describes a method of loading a self-expanding stent (stent 100 ... may be made self-expanding, para[0128]) onto a delivery guide (insertion in a blood vessel or other tissue by insertion means, wherein the insertion means include a suitable catheter, or flexible rod, para[0128]), the method comprising: holding the stent compressed to a reduced diameter configuration (stent 100 has been formed it may be compressed, para[0128]) in at least one sleeve (the stent to include one or more ... sleeves, para[0396); engaging the stent with the delivery guide (a suitable catheter, or flexible rod, para[0128]); and twisting the stent while in the sleeve (twisting it into a braided configuration, para[0128]).

As per claim 4, Falotico describes the method of claim 3, further comprising compressing the stent before loading the stent (after the stent 100 has been formed it may be compressed so as to occupy a space sufficiently small as to permit its insertion in a blood vessel or other tissue by insertion means, para[0128]) into the at least one sleeve (the stent to include one or more ... sleeves, para[0396).

As per claim 5, Falotico describes the method of claim 3, wherein a plurality of sleeves hold the stent (the stent to include ... sleeves ... for positioning a system component, para[0396]).

As per claim 7, Falotico describes the method of claim 3, further comprising removing the at least one sleeve from the stent (delivery of self-expanding stents which typically require the retraction of a delivery sheath, para[0439]).

Claim 6 lacks an inventive step under PCT Article 33(3) as being obvious over Falotico. Faltico describes a method of claim 5 wherein the stent is twisted (twisting it into a braided configuration, para[0128]) and has a plurality of sleeves (the stent to include one or more ... sleeves, para[0396). It would have been obvious to one skilled in the art to twist the stent by rotating the sleeves which cover them.

Claims 8, 10, 12, 14, 15, 30 and 35-38 lack novelty under PCT Article 33(2) as being anticipated by US 6,168,618 B1 (Frantzen).

As per claim 8, Frantzen describes a stent delivery system comprising: a delivery guide body having a distal portion (distal end 22 of catheter 21, (col 3, ln 32-46) and at least one elongate member including an electrolytically erodable section (binding straps 30 to erode via electrolytic action, (col 3, ln 10-15)); a stent comprising a near end, a far end and a structure extending therebetween (stent 10, FIG. 2, (col 3, ln 15-22)), at least one of the near and far end of the stent held in contact with the elongate body; wherein release of the erodable section initiates stent release (straps that causes them to erode, thus permitting the stent to partially or fully expand (col 3, ln 5-8)).

As per claim 10, Frantzen describes the system of claim 8, wherein at least one elongate member passes through the near or far end of the stent (guide wire 40, FIG. 2).

----Please See Supplemental Box-----